The CEO shareholder letter outlines Aclarion’s push to secure reimbursement from regional insurers in the United States and advance payer adoption in the United Kingdom. It emphasizes ongoing engagement with physicians and imaging centers to bolster clinical evidence and expand Nociscan platform uptake.

Aclarion’s CLARITY clinical trial is progressing toward an initial interim data readout scheduled for Q4 2026, which will provide early insights into the efficacy of its Nociscan diagnostic technology. The trial’s results are positioned as a key catalyst for regulatory and commercial advancement.

The company reports a strong balance sheet with cash runway extending into 2028, underlining its ability to fund operations and milestone-driven activities through multiple years. This financial stability supports ongoing clinical, regulatory, and commercialization initiatives without near-term capital raises.